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Abstract
Background Colonoscopy is the most widely used test to
screen for colorectal cancer but its use may be hindered by
patients’ inability to complete the bowel preparation.
Patient-reported satisfaction with bowel-cleansing prepa-
rations has received little attention. We assessed the reli-
ability and validity of a patient satisfaction survey used in
two large, multicenter, randomized, assessor-blinded
colonoscopy trials.
Methods Datasets from two pivotal trials were combined.
Patients in both trials included men and women aged
18–80 years who were scheduled for an elective outpatient
colonoscopy. Questions relevant to satisfaction with bowel
preparation prior to colonoscopy were identified from the
literature and incorporated into a 7-item survey adminis-
tered to patients on the day of colonoscopy. Domain 1 of
the satisfaction measure assessed difficulty using bowel-
cleansing preparations, ability to consume preparations,
acceptability of taste, and overall experience; questions
regarding acceptance or refusal of future use of the same
bowel preparation were asked in Domain 2. Responses
from each item of Domain 1 were transformed on a scale
ranging from 0 to 100 and summed as total satisfaction
scores. Cronbach’s alpha was used to measure reliability;
validity was assessed by evaluating relationship between
total satisfaction (Domain 1) and willingness to use
preparation in the future (Domain 2).
Results Mean age of the 1211 trial participants was 56:
61 % female, 89.5 % Caucasian. Domain 1 had a Cron-
bach’s alpha of 0.79, with higher satisfaction predicting
higher future acceptability (p\ 0.0001).
Conclusion The patient-reported satisfaction measure of
bowel-cleansing preparations possesses good validity and
reliability.
Key Points for Decision Makers
The patient survey on the tolerability and satisfaction
on the use of a precolonoscopy bowel-cleansing
preparation is reliable and valid.
The patient satisfaction survey predicts patients’
willingness to use bowel-cleansing preparation for
future colonoscopy.
1 Introduction
Colonoscopy is a minimally invasive endoscopic exami-
nation of the colon widely used for the diagnosis and
treatment of colon disorders [1]. It is the most commonly
used test to screen for colorectal cancer (CRC); results
from case–control studies suggest that colonoscopy is
associated with a 50 % reduction in CRC development [2]
and a 60–67 % reduction in CRC deaths [3, 4]. However,
adherence of the general population to CRC screening by
colonoscopy is lower than expected [5] owing to fear of
discomfort or complications, embarrassment, and
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unpleasant experience with precolonoscopy bowel-cleans-
ing preparations [6, 7].
Patient-reported outcomes (PROs) are regarded as clin-
ically important endpoints by regulatory agencies. The
measurement of satisfaction is important in light of studies
showing that satisfied patients are more likely to comply
with prescribed treatments and maintain a relationship with
a specific care provider [8]. A retrospective review of 15
studies on patient satisfaction with colonoscopy revealed
that of those patients who had undergone colonoscopy,
nearly 95 % were very satisfied with the colonoscopy
experience and 73–100 % were willing to repeat the pro-
cedure in the future [9]. However, most studies reporting
on patients’ satisfaction with colonoscopy have focused on
the overall experience rather than specifically on the
bowel-cleansing preparations.
In 2012, Prepopik (Ferring Pharmaceuticals Inc., Par-
sippany, NJ, USA), a dual-action, non-phosphate, low-
volume bowel-cleansing preparation containing sodium
picosulfate and magnesium citrate (P/MC), was approved
by the US FDA based on results from the Safety and
Efficacy of Dual-Action, Low-Volume Bowel Preparation:
An Evaluation of Colon Cleansing in Day-Before and
Split-Dose Regimens (SEE CLEAR) I and II trials [10, 11].
In both trials, tolerability and satisfaction of the bowel
preparation was assessed as a secondary endpoint using a
PRO survey created by the clinicians who designed the
SEE CLEAR trials [10, 11]. The objective of the present
study was to evaluate the reliability and validity of the
patient satisfaction survey used in the pivotal trials. As part
of the validity assessment, we evaluated the relationship
between patient satisfaction and patients’ self-reported
willingness to accept the same bowel preparation agent for
a future procedure.
2 Materials and Methods
2.1 Data Source
Patient demographics were similar across treatment groups
in SEE CLEAR I and II [10, 11]; thus, data from SEE
CLEAR I and II were combined in this current study
(Table 1). The study designs of the two trials were iden-
tical, with the exception of the timing of P/MC adminis-
tration, i.e. day-before versus split-dose administration. To
be eligible for either study, patients were required to have
had at least three spontaneous bowel movements per week
for 1 month prior to the scheduled colonoscopy. Patients
with renal insufficiency (serum creatinine clearance outside
the normal range [45–84 lmol/L for women and
59–104 lmol/L for men]) and serum potassium outside the
normal range (3.6–5.2 mmol/L) were excluded from the
study. Patients with active inflammatory bowel disease,
colonic disease, gastrointestinal disorders, or a previous
colorectal or upper gastrointestinal surgery were also
excluded. Additional details regarding study design and
patient populations can be found in the full published
reports [10, 11].
During the design of the SEE CLEAR studies, items
relevant to a patient’s experience with bowel cleansing
were identified from a review of the literature, and were
used to assemble the survey [12–16]. The survey con-
sisted of seven unique questions that were separated into
two domains for the present analysis: Domain 1 related to
a patient’s current satisfaction, and Domain 2 related to
future willingness to use the same preparation (Table 2).
The two domains were utilized to investigate the rela-
tionship between a patient’s satisfaction with their current
bowel preparation and the willingness to undergo bowel
Table 1 Patient demographics (ITT population)











2-L PEG ? bis
[n = 302]
Mean age, years (range) 54.8 (22–77) 55.7 (1–80) 56.8 (21–78) 56.2 (18–79)
Age, years [n (%)]
18–64 253 (83) 250 (84) 236 (80) 247 (82)
C65 52 (17) 48 (16) 60 (20) 55 (18)
Sex [n (%)]
Male 124 (41) 124 (42) 104 (35) 113 (37)
Female 181 (59) 174 (58) 192 (65) 189 (63)
Median BMI, kg/m2 (range) 29.4 (18.3–49.8) 29.6 (16.6–54.4) 29.19 (17.5–45.5)a 29.54 (16.80–51.32)
BMI body mass index, ITT intent-to-treat, 2-L PEG ? bis 2-L polyethylene glycol solution ? two 5-mg bisacodyl tablets, P/MC sodium
picosulfate and magnesium citrate
a n = 293 patients as the measurements needed to calculate BMI at baseline were missing for some patients
28 H. T. Hatoum et al.
preparation in a future colonoscopy. Domain 1 included
four items assessing the ease or difficulty of consuming
the bowel-cleansing preparation, whether the patient was
able to consume the entire preparation, the taste of the
preparation, and the overall experience when using the
preparation. Patients reported on their ability to complete
the entire preparation with a binary ‘yes’ or ‘no’ response.
The three other questions in Domain 1 required patients
to report satisfaction on a five-point scale (Table 2).
Domain 2 included two additional ‘yes/no’ questions to
assess participants’ willingness to accept or refuse the
same bowel preparation in a future colonoscopy. One
final question (question 7) asked patients to report details
of any prior colonoscopy and bowel preparation experi-
ence. As this final question did not relate to a patient’s
satisfaction with their current bowel preparation, question
7 was not included in the analysis. Bowel cleanse quality
was rated by the endoscopist using a modified version of
the Aronchick scale and the Ottawa scale. Patients were
classified as responders (successful bowel cleansing) if
the rating was ‘excellent’ or ‘good’ on the Aronchick
scale [17], or ‘excellent’, ‘good’, or ‘fair’ on the Ottawa
scale [12].
2.2 Statistical Analyses
The three items of Domain 1 with a five-point scale were
assigned scores from 0 to 4, with 0 representing the most
favorable and 4 representing the least favorable answers;
the dichotomous item was coded as 0 for yes and 1 for no.
The raw score of each of the four items was then trans-
formed to a range from 0 to 100 to standardize items. These
values were then summed to generate a total satisfaction
score between 0 and 400, where a lower score indicates
higher satisfaction. The total converted numerical scores
were compared between patients receiving P/MC versus
2-L polyethylene glycol (PEG)-3350 and two 5-mg bisa-
codyl tablets (PEG ? bis). In Domain 2, acceptability of
the preparations was evaluated based on participants’
responses as to whether they would accept or refuse the
bowel-cleansing preparation for a future colonoscopy.
Psychometric properties of the satisfaction survey, includ-
ing internal consistency reliability (the degree to which
individual questions within the survey are related to each
other [18]) and validity (the degree to which an instrument
is relevant to or valid in what it is purported to measure
[19]) were evaluated. A survey of the literature conducted
during the development of the questionnaire did not find an
existing validated measure of patient satisfaction in patients
undergoing bowel preparation prior to colonoscopy. In the
present analysis, predictive validity was established by
evaluating whether total satisfaction scores could predict a
patient’s willingness to accept or refuse the same bowel
preparation for a future colonoscopy.
Cronbach’s alpha was used to measure the internal
consistency of patients’ responses to the individual ques-
tions of Domain 1 of the satisfaction questionnaire. Values
above 0.70 reflect acceptable reliability (internal consis-
tency) [20]. The validity of the patient satisfaction instru-
ment was assessed by determining the ‘discrimination’ and
the ‘predictive validity’ of test scores. Discrimination was
assessed by examining the extent of floor and ceiling
effects, as measured by the percentages of responses at
either end of the response range using the raw item scores
(an item is considered to have a ceiling effect if most
responses fall on its highest value) [21]. The distribution of
responses to the four questions of Domain 1 were examined
as to their possible ceiling/floor effects based on the crite-
rion of[15 % of responses at the extreme end of the scale
[22]. The predictive validity was determined by evaluating
the relationship between the satisfaction scores (Domain 1)
and the acceptability measure on the likelihood to accept the
same preparation in the future (Domain 2). The relationship
between transformed satisfaction scores and the proportions
of responders and nonresponders, defined according to the
trials’ clinical endpoints, was also assessed; patients with































5. Would you ask your doctor for this
preparation again if you needed another
colonoscopy in the future?
Yes
No
6. Would you refuse the same preparation
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incomplete satisfaction surveys or missing efficacy mea-
surements were excluded from this analysis.
All continuous variables were checked for normality.
Wilcoxon rank sum test was used for variables found to be
non-normally distributed. Associations between total
transformed satisfaction scores and willingness to use the
preparation in the future, and between total transformed
satisfaction scores and efficacy were analyzed by Wilcoxon
rank sum test. All analyses were carried out using SAS 9.1
statistical software (SAS Institute, Inc., Cary, NC, USA).
3 Results
A total of 1211 patients were randomized to receive P/MC
or PEG ? bis across the two trials. Not all study partici-
pants completed the treatment or finished the entire satis-
faction questionnaire; thus, the sample size used in this
analysis was smaller than the 1211 patients who partici-
pated in the two trials. Six of the 608 (0.98 %) participants
in the SEE CLEAR I study and 10 of the 603 (1.66 %)
participants in the SEE CLEAR II study did not complete
the patient satisfaction questionnaire and were excluded
from the analysis. The mean age of the entire study pop-
ulation was 56 years, 61 % were female, and 89.5 % were
Caucasian. Patient characteristics for the safety populations
from SEE CLEAR I and II are shown in Table 1. The mean
(standard deviation) transformed total satisfaction score of
the entire study population was 97.2 (75.3), suggesting that
most patients were satisfied with the study preparations;
median score was 100. The distribution of responses to
each of the satisfaction survey questions in Domain 1 is
shown in Fig. 1. The total transformed satisfaction score
was significantly better for patients administered P/MC
versus PEG ? bis (median: P/MC vs. PEG ? bis, 50 vs.
120; p\ 0.0001) (Table 3).
Domain 1 yielded a Cronbach’s alpha of 0.79. The
distribution of responses indicated a possible floor effect
(denoting higher satisfaction) for three of four items related
to satisfaction. For item 1 (difficulty in consuming the
bowel-cleansing preparation), 35 % of the subjects
responded with the lowest possible score (i.e. ‘very easy to
use’); for item 2 (ability to consume the preparation as
instructed), 95 % of the subjects responded with ‘yes’; and
for item 3 (overall experience with the preparation), nearly
77 % subjects responded with ‘excellent’ or ‘good’. The
analysis of predictive validity showed that total satisfaction
scores were significantly better in patients who would
accept the same bowel-preparation agent in a future colo-
noscopy compared with patients who would refuse it
(median: 75 vs. 150, accept vs. refuse; p\ 0.0001; Wil-
coxon rank sum test) (Table 4).
Among the study population that completed all survey
questions, 960 (80.3 %) and 954 (79.8 %) patients were
deemed responders using the Aronchick and Ottawa scales,
respectively. According to either scale, responders had
better total satisfaction scores compared with nonrespon-
ders [median: 75 vs. 100, responders vs. nonresponders for
both the Aronchick scale (Table 5) and the Ottawa scale
(Table 6)]; however, the differences according to either
efficacy scale were not statistically significant (Table 4).
4 Discussion
Overall patient satisfaction regarding bowel-cleansing
preparations is an important component in the CRC
screening process as it may play a role in ensuring that the
preparation is successfully consumed as instructed. Despite
Fig. 1 Distribution of responses to the satisfaction survey questions.
Items 1, 3, and 4 had five-point scales: very easy, easy, tolerable,
difficult, very difficult; or excellent, good, fair/tolerable, poor, bad.
Item 2 had a two-point scale: yes and no
Table 3 Comparison of total satisfaction score between patients
administered P/MC vs. 2-L PEG ? bis
Items P/MC 2-L PEG ? bis p valuea
Total satisfaction scoreb \0.0001
Median (interquartile range) 50 (50) 120 (75)
Minimum, maximum 0, 250 0, 400
P/MC sodium picosulfate and magnesium citrate, 2-L PEG ? bis 2-L
polyethylene glycol solution ? two 5-mg bisacodyl tablets
a Based on the Wilcoxon rank sum test
b Sum of items 1–4. Survey items 1, 3, and 4 had five-point scales
(very easy, easy, tolerable, difficult, very difficult; or excellent, good,
fair/tolerable, poor, bad) and were assigned scores from 0–4, with 0
representing most favorable (e.g. very easy or excellent) and 4 rep-
resenting least favorable (e.g. very difficult or bad). Item 2 (‘‘Were
you able to consume the entire preparation as instructed?’’) was coded
as 0 for yes and 1 for no. Raw scores of each of the four items were
transformed to a range of 0–100 (corresponding to 0–4 on the original
five-point scale or 0–1 if yes/no) and summed up to a total score,
yielding a total score range between 0 and 400, with lower scores
indicating higher satisfaction
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its importance, until recently no standardized survey was
available to specifically measure patient satisfaction in
bowel-cleansing preparations before colonoscopy [23]. We
report that Domain 1 of the satisfaction survey adminis-
tered in the two SEE CLEAR clinical trials exhibits
internal consistency reliability. The Cronbach’s alpha
reliability coefficient derived in our study is similar to
coefficients of 0.60–0.78 reported by Sint Nicolaas and
colleagues [23] for the five modules of a survey designed to
assess patient experience with colonoscopy. We also found
Table 4 Predictive validity of
the patient satisfaction survey
Item Total satisfaction score,a median p valueb
Accept Refuse Responder Nonresponder
Likely to accept vs. refuse future colonoscopy 75 150 \0.0001
Responder vs. nonresponder (Aronchick scale) 75 100 0.7984
Responder vs. nonresponder (Ottawa scale) 75 100 0.4358
a Sum of items 1–4. Survey items 1, 3, and 4 had five-point scales (very easy, easy, tolerable, difficult, very
difficult; or excellent, good, fair/tolerable, poor, bad) and were assigned scores from 0–4, with 0 repre-
senting most favorable (e.g. very easy or excellent) and 4 representing least favorable (e.g. very difficult or
bad). Item 2 (‘‘Were you able to consume the entire preparation as instructed?’’) was coded as 0 for yes and
1 for no. Raw scores of each of the four items were transformed to a range of 0–100 (corresponding to 0–4
on the original five-point scale or 0–1 if yes/no) and summed up to a total score, yielding a total score range
between 0 and 400, with lower scores indicating higher satisfaction
b Based on the Wilcoxon rank sum test
Table 5 Satisfaction score and
responders via the Aronchick
scale
Responder status Survey measure n Raw score [mean (SD)] Median
No Easy/difficult 232 1.19 (1.07) 1.00
Able to consume the entire preparation 233 0.05 (0.21) 0.00
Overall experience 232 1.00 (0.92) 1.00
Taste of study preparation 233 1.50 (0.99) 1.00
Total satisfactiona 231 97.5 (74.43) 100.0
Yes Easy/difficult 955 1.18 (1.11) 1.00
Able to consume the entire preparation 955 0.05 (0.21) 0.00
Overall experience 953 0.98 (0.90) 1.00
Taste of study preparation 956 1.53 (0.96) 2.00
Total satisfactiona 951 96.7 (74.93) 75.00
SD standard deviation
a Transformed score
Table 6 Satisfaction score and
responders via the Ottawa scale
Responder status Survey measure n Raw score [mean (SD)] Median
No Easy/difficult 192 1.22 (1.10) 1.00
Able to consume the entire preparation 193 0.07 (0.25) 0.00
Overall experience 191 1.01 (0.91) 1.00
Taste of study preparation 193 1.51 (0.96) 2.00
Total satisfactiona 190 100.92 (75.91) 100.00
Yes Easy/difficult 992 1.18 (1.11) 1.00
Able to consume the entire preparation 992 0.04 (0.20) 0.00
Overall experience 991 0.98 (0.91) 1.00
Taste of study preparation 993 1.53 (0.96) 2.00
Total satisfactiona 989 96.26 (74.58) 75.00
SD standard deviation
a Transformed score
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that Domain 1 of the satisfaction survey is able to predict
patients’ willingness to accept the same bowel preparation
in the future.
An updated literature review revealed two scales
developed to assess patients’ overall satisfaction with
endoscopy or to measure and improve the quality of
endoscopy: a modified Group Health Association of
America nine-item survey [24] and the Global Rating Scale
(GRS) of the Royal College of Physicians Joint Advisory
Group on GI Endoscopy [25], respectively. The GRS has
four primary measures/domains: clinical quality, quality of
patient experience, training, and workforce [25]. Of note,
neither measure directly addresses patients’ satisfaction
and/or tolerance of bowel-cleansing preparation [23, 25–
28]. Patel and colleagues have recently reported the
development and validation of a nine-item tolerability
questionnaire in patients who underwent bowel preparation
for colonoscopy [29]. Although no data are yet available
using this questionnaire, the authors hypothesize a rela-
tionship may exist between bowel preparation tolerance
and bowel cleanse quality. In our study, we did not observe
any difference in total patient satisfaction scores between
responders and nonresponders; however, significantly bet-
ter satisfaction scores were found in patients who reported
they would accept the same bowel preparation for a future
colonoscopy. Similarly, Sint Nicolaas and colleagues
reported that lower satisfaction due to a burdensome bowel
preparation decreased a patient’s willingness to repeat the
procedure in the future [23].
Possible floor effects were observed in three of the four
items in Domain 1. Several observations can be made to
explain this finding. Items selected for this portion of the
survey were assembled with the express purpose of mea-
suring satisfaction in patients who willingly enrolled in a
clinical trial and were fully aware of their need for colo-
noscopy. Thus, a uniform distribution of scores along the
possible range of responses is highly unlikely. More
importantly, the satisfaction survey was constructed to
measure one domain (dimension) related to the patient’s
satisfaction with the bowel-preparation process. Theoreti-
cally, the floor and ceiling effects may not be as exagger-
ated in a general population survey, but this is not feasible
here because the responses are skewed based on actual
consumption of the colonoscopy preparation. Moreover,
the observation that three of the four items in Domain 1 had
a floor effect conservatively biased the results. Because a
lower score denotes higher satisfaction, expanding the
range on the satisfaction side would result in higher overall
satisfaction scores.
The ability of a patient to completely consume the
bowel preparation and its accompanying fluids is a key
factor in achieving a high-quality colon cleansing and a
successful colonoscopy. It stands to reason that patients
with better satisfaction would be more compliant with
ingesting the entire bowel preparation, which presumably
would achieve better colon cleansing. However, our ability
to assess this based on results from SEE CLEAR I and II
[10, 11] is limited for two reasons. First, in these trials,
there was a considerable floor effect in three of four survey
items, with the majority of study patients providing
favorable responses to the survey questions regardless of
the bowel-cleansing preparation they received. Second,
99.3 % and 91.1 % of patients were able to ingest the
entire P/MC and PEG ? bis preparation, respectively,
resulting in a high compliance rate, and the rate of suc-
cessful cleansing was 83.6 % and 77.1 % for patients
administered P/MC and PEG ? bis, respectively, using the
Aronchick scale. Because of the disproportionate number
of subjects considered responders, the difference in satis-
faction scores between responders and nonresponders did
not reach statistical significance.
An additional limitation of our analysis was that the
patient satisfaction survey was not validated against an
existing validated measure. During the design of the
studies, a literature search failed to find any existing vali-
dated measure of patient satisfaction for bowel preparation
prior to colonoscopy. Accordingly, the current analysis
used the patient’s self-reported willingness to ask for the
same preparation at a future colonoscopy as a proxy
measure of satisfaction. Additionally, studies with greater
diversity in bowel preparation agents will be needed to
more fully characterize patient satisfaction in patients
preparing for colonoscopy.
Based on the short duration of the two trials investigated
here, we cannot directly speak to the long-term benefit of
appropriate screening in terms of minimizing the incidence
of colon cancer. However, it could be argued that the
potential long-term beneficial impact of the appropriate
screening and bowel-cleansing preparation should not be
ignored, given that the removal of precancerous adeno-
matous polyps during colonoscopy has been cited as one of
the factors leading to a steady decline in CRC incidence
over the past 30 years [30]. Bowel preparations that allow
for better visualization will facilitate the detection and
removal of adenomatous polyps, and patient compliance
when taking a bowel preparation will have a favorable
impact on this overall surveillance process.
5 Conclusions
The patient satisfaction survey measure used in the SEE
CLEAR I and II trials was found to be reliable and valid.
Overall, subjects who were more satisfied with their bowel-
cleansing preparation were more likely to accept the same
preparation in the future.
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